Document is current
Any future updates will be listed below
-
Authors
Blauvelt, Andrew https://orcid.org/0000-0002-2633-985X
Gooderham, Melinda https://orcid.org/0000-0001-8926-0113
Bhatia, Neal https://orcid.org/0000-0001-7448-7809
Langley, Richard G.
Schneider, Shannon
Zoidis, John
Kurbasic, Azra https://orcid.org/0000-0002-1910-2619
Armstrong, April
Silverberg, Jonathan I. https://orcid.org/0000-0003-3686-7805
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03131648 at ClinicalTrials.govnct03160885 at ClinicalTrials.govDocuments that mention this clinical trial
Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1
https://doi.org/10.1007/s40257-023-00817-0
Long-Term Disease Control and Minimal Disease Activity of Head and Neck Atopic Dermatitis in Patients Treated with Tralokinumab up to 4 Years
https://doi.org/10.1007/s40257-025-00931-1
Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials
https://doi.org/10.1007/s40257-023-00806-3
Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3
https://doi.org/10.1007/s13555-022-00805-y
nct03363854 at ClinicalTrials.govDocuments that mention this clinical trial
Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1
https://doi.org/10.1007/s40257-023-00817-0
Long-Term Disease Control and Minimal Disease Activity of Head and Neck Atopic Dermatitis in Patients Treated with Tralokinumab up to 4 Years
https://doi.org/10.1007/s40257-025-00931-1
Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials
https://doi.org/10.1007/s40257-023-00806-3
Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3
https://doi.org/10.1007/s13555-022-00805-y
Documents that mention this clinical trial
Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis
https://doi.org/10.1007/s40257-022-00702-2
Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3
https://doi.org/10.1007/s13555-022-00805-y
-
Funding
Funding for this research was provided by:
LEO Pharma A/S
- License Information
-
More Information
Article History
Received: 7 May 2022
Accepted: 30 August 2022
First Online: 24 September 2022
